Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04526106
Title First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Relay Therapeutics, Inc.
Indications

Advanced Solid Tumor

Therapies

RLY-4008

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP

Additional content available in CKB BOOST